Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis - Université de Lorraine
Journal Articles New England Journal of Medicine Year : 2019

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Bruce Sands
  • Function : Author
Icahn School of Medicine at Mount Sinai [New York]
Laurent Peyrin-Biroulet
Centre Hospitalier Régional Universitaire de Nancy
Edward Loftus
  • Function : Author
Mayo Clinic [Rochester]
Silvio Danese
Humanitas Clinical and Research Center [Rozzano, Milan, Italy]
Jean-Frédéric Colombel
  • Function : Author
Murat Törüner
  • Function : Author
Laimas Jonaitis
  • Function : Author
Brihad Abhyankar
  • Function : Author
Jingjing Chen
  • Function : Author
Raquel Rogers
  • Function : Author
Richard Lirio
  • Function : Author
Jeffrey Bornstein
  • Function : Author
Stefan Schreiber
  • Function : Author
University Hospital Schleswig-Holstein [Kiel, Germany]

Domains

Life Sciences [q-bio]

Djésia Arnone  : Connect in order to contact the contributor

https://hal.univ-lorraine.fr/hal-03144487

Submitted on : Wednesday, February 17, 2021-4:24:47 PM

Last modification on : Tuesday, October 10, 2023-10:22:40 AM

Consult the full text

Dates and versions

hal-03144487 , version 1 (17-02-2021)

Identifiers

Cite

Bruce Sands, Laurent Peyrin-Biroulet, Edward Loftus, Silvio Danese, Jean-Frédéric Colombel, et al.. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 2019, 381 (13), pp.1215-1226. ⟨10.1056/NEJMoa1905725⟩. ⟨hal-03144487⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-LORRAINE
20 View
0 Download

Altmetric

Share

More